Let the Numbers be Your Guide in Managing Patients with Liver Disease
Intended Use / Indications for Use

The FibroScan® system is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. FibroScan® is indicated for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). The shear wave speed and stiffness, and CAP may be used as an aid to clinical management of adult patients with liver disease.

Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.
FibroScan®: An Advance in Liver Monitoring

- The first device FDA-cleared as an aid to clinical management of patients with liver disease
- Quantitatively measures liver stiffness and the rate of ultrasound attenuation at the same time
  ➔ Both of which can be of assistance in managing patients with liver disease
- The examined volume is 3cm³, over 100x that of a needle biopsy
- Recognized in most guidelines and included as a non-invasive assessment tool for most drugs in clinical development for liver disease
FibroScan® is designed to provide consistent results over time and operators

- The procedure is quick and painless – providing instant results
- Directs the operator through the examination with clear visual direction
  - As a quality control measure, the exam consists of 10 quick measurements
  - Each FibroScan® contains factory preset algorithms to provide consistent results across FibroScan® machines
- Preselects the right probe for different patient morphometry
  - S Probe for pediatric patients
  - M Probe for most adult patients
  - XL Probe for larger adult patients
Precise Measurements to Inform Treatment Decisions

- Liver stiffness calculated using patented Vibration-Controlled Transient Elastography (VCTE™)
- Mechanical vibration creates shear waves, and that speed is measured by an ultrasound signal
  ➔ Higher speeds indicate stiffer liver tissue
- The CAP™ attenuation rate for the ultrasound signal is measured simultaneously and can provide important information about the state of the liver
- Unlike radiation pressure techniques, VCTE™ uses controlled frequency for consistent, reproducible results
FibroScan® is a recognized standard for non-invasive liver assessment

- FibroScan® is the reference for non-invasive measurement of liver stiffness in the guidelines of major liver associations (AASLD, EASL, ALEH & APASL) and the WHO
- Subject of more than 1,300 peer-reviewed publications worldwide*
- Included as a liver assessment option in most clinical trials for drugs in development for liver disease
- Covered by most insurance plans

*These articles represent uses of the FibroScan® in published literature, and Echosens does not intend to make any of the specific claims found in these articles. The FibroScan® is a tool to aid in the clinical management of liver disease, and is not intended for the treatment of any specific liver disease or condition.